Roland Schmieder (Germany) answers the following questions:
- Please share with us your thoughts on the Symplicity HTN-3 press release
- How has this new information impacted your clinical practice as related to renal denervation?
- What is the vision of ESH on this matter?
- What are the most significant advancements in hypertension treatments in the past 5 years?
To leave a comment, please create your free account here !